Others

Alongside our three main therapeutic areas, there are other molecules that we are currently developing. One of these is the sclerostin antibody, an antibody for the treatment of bone loss disorders such as osteoporosis. This is being developed in conjunction with Amgen.

In addition, fesoterodine has been submitted to the FDA and the EMEA for the treatment of overactive bladder. In 2006, an exclusive worldwide licence was granted to Pfizer for the further development and commercialisation of fesoterodine.